


PRODUCT INFORMATION



Quipazine (maleate)

Item No. 42262

CAS Registry No.: 150323-78-7
Formal Name: 2-(1-piperazinyl)-quinoline, (2Z)-2-butenedioate (1:2)
MF: C₁₃H₁₅N₃ • 2C₄H₄O₄
FW: 445.4
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Quipazine (maleate) is supplied as a solid. A stock solution may be made by dissolving the quipazine (maleate) in the solvent of choice, which should be purged with an inert gas. Quipazine (maleate) is sparingly soluble (1-10 mg/ml) in DMSO.

Quipazine (maleate) is slightly soluble (0.1-1 mg/ml) in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

Quipazine is an agonist of the serotonin (5-HT) receptor subtypes 5-HT_{2A}, 5-HT_{2B}, and 5-HT_{2C}.¹ It induces calcium accumulation in CHO-K1 cells expressing 5-HT_{2A}, 5-HT_{2B}, or 5-HT_{2C} (EC₅₀s = 309.03, 177.83, and 338.84 nM, respectively, for the human receptors). Quipazine also binds to the 5-HT₃ receptor (K_i = 2.1 nM).² It decreases food intake in rats when administered at doses of 2.5, 5, or 10 mg/kg.³ Quipazine (0.3 mg/kg per day), in combination with 8-hydroxy DPAT (Item No. 22608), electrode stimulation of dorsal and lumbar spine regions, and locomotor training, restores spinal circuitry function, improves gait regularity, and increases interlimb coordination and limb weight-bearing in a rat model of hindlimb paralysis induced by spinal cord transection.⁴

References

1. Porter, R.H.P., Benwell, K.R., Lamb, H., *et al.* Functional characterization of agonists at recombinant human 5-HT_{2A}, 5-HT_{2B} and 5-HT_{2C} receptors in CHO-K1 cells. *Br. J. Pharmacol.* **128**(1), 13-20 (1999).
2. Schiavi, G.B., Brunet, S., Rizzi, C.A., *et al.* Identification of serotonin 5-HT₄ recognition sites in the porcine caudate nucleus by radioligand binding. *Neuropharmacology* **33**(3-4), 543-549 (1994).
3. Samanin, R., Bendotti, C., Miranda, F., *et al.* Decrease of food intake by quipazine in the rat: Relation to serotonergic receptor stimulation. *J. Pharm. Pharmacol.* **29**(1), 53-54 (1977).
4. Courtine, G., Gerasimenko, Y., van den Brand, R., *et al.* Transformation of nonfunctional spinal circuits into functional states after the loss of brain input. *Nat. Neurosci.* **12**(10), 1333-1342 (2009).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/18/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM